FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 11/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 11/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of November 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 8,390m
  • Biotech received 41% of the total investment volume (-1% compared to the previous month)
  • Oncology dominates as the top indication in Biotech
  • VectorY Therapeutics (Netherlands) has the highest transaction volume of EUR 129m in November, followed by EyeBio (United Kingdom) EUR 122m and NMD Pharma (Denmark) EUR 75m
  • The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Forbion (Netherlands) and Jeito (France)
  • Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.

By Mathias KlozenbücherJohannes Link and Marco Buonafede-Bennardo.